类风湿关节炎治疗药物的研发进展及趋势

被引：150

作者：

胡晓敏 ^{[1
]}

宗英 ^{[2
]}

余珊珊 ^{[1
]}

袁伯俊 ^{[2
]}

陆国才 ^{[2
,3
]}

王庆利 ^{[1
]}

机构：

[1] 国家食品药品监督管理总局药品审评中心

[2] 上海第二军医大学卫生毒理学教研室

[3] 苏州华测生物技术有限公司

来源：

中国新药杂志 | 2017年 / 26卷 / 01期

关键词：

类风湿关节炎; 自身免疫; 细胞因子; 抗体药物; JAK抑制剂; IL-6抑制剂;

D O I：

暂无

中图分类号：

R977 [影响生长代谢机能药物];

学科分类号：

100710 [药物代谢动力学];

摘要：

类风湿关节炎(RA)是一种发生在滑膜关节及其他器官系统的慢性、全身性、炎症性疾病,也是一种慢性进行性自身免疫性疾病。RA发病机制不清,与遗传因素、细菌和病毒因素、T细胞及B细胞亚群的聚集、大量促炎性细胞因子活化等相关。目前常用的RA治疗药物有改善病情的抗风湿药(DMARDs)、非甾体类抗炎药(NSAIDs)、糖皮质激素、生物制剂以及靶向小分子药物等。本文简要综述RA的发病机制以及RA治疗药物的研发进展和趋势,以期为RA治疗及相关的新药研发提供参考。

引用

页码：36 / 43

页数：8

共 15 条

[1]

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis [J].

Rovin, Brad H. ;

van Vollenhoven, Ronald F. ;

Aranow, Cynthia ;

Wagner, Carrie ;

Gordon, Robert ;

Zhuang, Yanli ;

Belkowski, Stanley ;

Hsu, Benjamin .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (09) :2174-2183

[2]

The Efficacy and Safety of Clazakizumab; an Anti–Interleukin‐6 Monoclonal Antibody; in a Phase IIb Study of Adults With Active Psoriatic Arthritis.[J].Philip J. Mease;Alice B. Gottlieb;Alberto Berman;Edit Drescher;Jun Xing;Robert Wong;Subhashis Banerjee.Arthritis & Rheumatology.2016, 9

[3]

Baricitinib for the treatment of rheumatoid arthritis [J].

Kubo, Satoshi ;

Nakayamada, Shingo ;

Tanaka, Yoshiya .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (09) :911-919

[4]

Silibinin Improves the Effects of Methotrexate in Patients with Active Rheumatoid Arthritis : Pilot Clinical Study.[J].Hussain ; Saad Abdulrahman | Mortada ; Ahmed Hashem | Jasim ; Nazar Abdulateef | Gorial ; Faiq Isho.Oman Medical Journal.2016, 4

[5]

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.[J].Florence Namour;Julie Desrivot;Annegret Van der Aa;Pille Harrison;Chantal Tasset;Gerben van';t Klooster.Drug Metabolism Letters.2016, 1

[6]

Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis.[J].L. Dinesh Kumar;R. Karthik;N. Gayathri;T. Sivasudha.Biomedicine & Pharmacotherapy.2016,

[7]

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis [J].

Genovese, Mark C. ;

van Vollenhoven, Ronald F. ;

Pacheco-Tena, Cesar ;

Zhang, Yanqiong ;

Kinnman, Nils .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (01) :46-55

[8]

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial [J].

van Vollenhoven, R. F. ;

Wax, S. ;

Li, Y. ;

Tak, P. P. .

ARTHRITIS & RHEUMATOLOGY, 2015, 67 (11) :2828-2836

[9]

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study [J].

Genovese, Mark C. ;

Fleischmann, Roy ;

Kivitz, Alan J. ;

Rell-Bakalarska, Maria ;

Martincova, Renata ;

Fiore, Stefano ;

Rohane, Patricia ;

van Hoogstraten, Hubert ;

Garg, Anju ;

Fan, Chunpeng ;

van Adelsberg, Janet ;

Weinstein, Steven P. ;

Graham, Neil M. H. ;

Stahl, Neil ;

Yancopoulos, George D. ;

Huizinga, Tom W. J. ;

van der Heijde, Desiree .

ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) :1424-1437

[10]

N08C9 (Alliance) - A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.[J].R.C. Miller;D.G. Petereit;J.A. Sloan;H. Liu;J.A. Martenson;J.D. Bearden;R. Sapiente;G.R. Seeger;M.J. Iott;C.L. Loprinzi.International Journal of Radiation Oncology; Biology; Physics.2013, 5

← 1 2 →